Management of Slightly Echogenic Hepatic Parenchyma

Initial Evaluation

The American College of Radiology recommends obtaining comprehensive liver biochemistry tests including ALT, AST, GGT, alkaline phosphatase, bilirubin, and albumin to assess liver function and determine the AST:ALT ratio, which can help distinguish between alcoholic and non-alcoholic fatty liver disease 1, 2
Screening for common causes of fatty liver disease should include a detailed alcohol intake history, assessment of metabolic risk factors such as obesity, type 2 diabetes, hypertension, and dyslipidemia, and exclusion of other liver diseases through serological testing 2, 3, 4
Calculation of non-invasive fibrosis scores, such as the FIB-4 index or NAFLD Fibrosis Score, can help stratify the risk of advanced fibrosis and guide management 3, 5

Ultrasound has limited sensitivity (53-65%) for detecting mild hepatic steatosis, and more accurate quantification of hepatic fat content can be achieved through controlled attenuation parameter (CAP) measurement with transient elastography or MRI-based techniques 1, 2, 4, 6

Patients with two or more metabolic risk factors have a significantly higher risk of progression to cirrhosis or hepatocellular carcinoma and require more thorough evaluation 5
For patients with intermediate or high risk of advanced fibrosis, elastography-based assessment and consideration of referral to hepatology may be necessary 4, 5, 6

Management of associated metabolic conditions, such as optimizing control of diabetes, hypertension, and dyslipidemia, is crucial for patients with NAFLD 2, 4
Consideration of referral to endocrinology for patients with poorly controlled metabolic disease may be necessary 5

For patients with simple steatosis and low risk of fibrosis, repeat liver function tests and non-invasive fibrosis assessment in 6-12 months may be sufficient 3, 4
For patients with evidence of NASH or significant fibrosis, more frequent monitoring (every 3-6 months) and consideration of liver biopsy may be necessary 3, 4

Ultrasound assessment of fatty liver is subjective and has significant inter-observer variability, and fatty liver can mask underlying focal lesions due to increased background echogenicity 2, 3
The presence of pancreatic steatosis, which often coexists with NAFLD, may be associated with insulin resistance 4
Normal kidney and spleen measurements can be reassuring findings that suggest absence of advanced chronic liver disease 1, 2

The combination of mildly coarsened liver echotexture on ultrasound and decreased attenuation on CT are highly specific imaging findings for fat accumulation in the liver parenchyma, according to the American College of Radiology 7, 8, 9
Decreased liver attenuation on CT is a specific indicator of hepatic steatosis, with liver parenchymal attenuation <40 HU correlating with ≥30% steatosis (moderate-to-severe disease), as reported by the Journal of the American College of Radiology 9
CT has 100% specificity but only 53.8-82% sensitivity for moderate-to-severe steatosis when using unenhanced imaging, according to the Clinical and Molecular Hepatology 8, 9
Progressive decreases in liver attenuation correlate with increasing fat content: 64.4 HU (0%), 59.1 HU (1-25%), 41.9 HU (26-50%), and 25.0 HU (>50%), as stated by the Journal of the American College of Radiology 9
Mildly coarsened (bright/echogenic) liver echotexture has 96% positive predictive value for steatosis of any degree, according to the Clinical and Molecular Hepatology 8

Screen for metabolic syndrome components: obesity (BMI), type 2 diabetes, hypertension, and dyslipidemia, as recommended by the Clinical and Molecular Hepatology 7, 8
Obtain transient elastography with CAP for simultaneous assessment of steatosis severity and liver stiffness in intermediate/high-risk patients, according to the Clinical and Molecular Hepatology 7
Optimize control of metabolic conditions (diabetes, hypertension, dyslipidemia) in intermediate/high-risk patients, as stated by the Clinical and Molecular Hepatology 7
Liver biopsy may be necessary for definitive diagnosis and staging in patients with evidence of advanced fibrosis, as reported by the Clinical and Molecular Hepatology 8